International Society on Thrombosis and Hemostasis Scientific and Standardization Committee, Subcommittee on Hemostasis and Malignancy guidance statements on cancer-associated venous thromboembolism management in the setting of thrombocytopenia. *Acute VTE defined as diagnosis of VTE within the previous 30 days and subacute/chronic greater than 30 days. †High risk of progression includes symptomatic segmental or more proximal pulmonary embolism, proximal deep vein thrombosis, or a history of recurrent/progressive thrombosis. Low risk events include distal deep vein thrombosis, incidental subsegmental pulmonary embolism, and catheter-related thrombosis. Platelet counts are reported in platelets ×10⁹/L. ¹If unable to maintain platelets of ≥40 to 50, a reduced dose is reasonable. ²Consider withholding LMWH if platelets are <50 in the low-risk group in subacute/chronic period. ³Consider prophylactic dose if platelets ≥10 during the acute period. UFH, unfractionated heparin. See Samuelson et al.³⁶